Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:allocates |
Randomized
|
| gptkbp:completedIn |
April 27, 2020
|
| gptkbp:condition |
gptkb:COVID-19
|
| gptkbp:enrollment |
2373
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT04280705
|
| gptkbp:intervention |
gptkb:Remdesivir
|
| gptkbp:location |
gptkb:China
|
| gptkbp:mask |
None (Open Label)
|
| gptkbp:period |
Phase 3
|
| gptkbp:principalInvestigator |
Bin Cao
|
| gptkbp:recognizedBy |
gptkb:NCT04280705
|
| gptkbp:result |
Time to clinical recovery
|
| gptkbp:sponsor |
gptkb:Gilead_Sciences
|
| gptkbp:startDate |
February 6, 2020
|
| gptkbp:status |
Completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:title |
A Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)
|
| gptkbp:bfsParent |
gptkb:ACTT-1
|
| gptkbp:bfsLayer |
6
|